Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...
Eli Lilly LLY announced results from the phase III ... The drug is marketed by Italy-based Menarini Group. AstraZeneca AZN is also developing its oral SERD drug, camizestrant, in multiple late ...
On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback